secwatch.observer — SEC 8-K summary
======================================

Issuer:     Krystal Biotech, Inc. (KRYS)
CIK:        0001711279
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001711279-22-000055
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KB407 CF gene therapy data: human CFTR expression 106–440% of endogenous in NHPs; IND accepted
--------------------------------------------------------------------------------

- KB407 transduced ciliated, club, and goblet cells in NHP airways; no transduction of basal cells.
- Human CFTR transcript levels reached 106–440% of endogenous NHP CFTR in lung biopsies.
- No adverse findings in GLP toxicology study; NOAEL at highest dose tested.
- FDA accepted KB407 IND in July 2022.
- No significant cytokine induction in human CF cells after KB407 transduction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711279/000171127922000055/0001711279-22-000055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711279/000171127922000055/krys-20221103.htm
  HTML page:      https://secwatch.observer/filing/0001711279-22-000055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer